MPS II Biomarkers - HSCC 2025

Dr. Joseph Muenzer, a world renowned expert in MPS, discusses biomarkers in MPS II. With the FDA's Accelerated Approval Pathways, biomarkers (or surrogate endpoints) have become a frequent topic of conversation. Learn what biomarkers are, how they are being used in the clinical trial process, and which biomarkers are assessed in MPS II.